SIMULATIONS PLUS INC

Simulations Plus insider trades reveal a “buy‑low, sell‑high” strategy, signaling confidence in its $375 M Altaris acquisition and the future of its drug‑discovery software.

Jill Fiedler‑Kelly’s 1,000‑share buy‑sell‑option play at Simulations Plus hints at confidence in its drug‑simulation platform, yet a negative P/E warns of risk.

DiBella’s 10b5‑1 sale of 1,000 Simulations Plus shares shows no ownership shift but signals exec confidence, hinting at upcoming partnerships and AI‑driven drug‑simulation gains.

Insider buying at Simulations Plus (SPMI) shows growing confidence and could spark a bullish turn—discover what this means for its drug‑simulation tech and future earnings.

Insider buy of 1,776 shares by Evans Sharlene at zero cost shows confidence in Simulations Plus, a niche simulation software firm amid a volatile market and emerging defense opportunities.